ALBUTEROL SULFATE
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $57,241 | 39 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $57,241 | 39 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma | Teva Pharmaceuticals USA, Inc. | $57,241 | 0 |
Top Doctors Receiving Payments for ALBUTEROL SULFATE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Savannah, GA | $57,241 | 39 |
Manufacturing Companies
- Teva Pharmaceuticals USA, Inc. $57,241
Product Information
- Type Drug
- Total Payments $57,241
- Total Doctors 0
- Transactions 39
About ALBUTEROL SULFATE
ALBUTEROL SULFATE is a drug associated with $57,241 in payments to 0 healthcare providers, recorded across 39 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2020 to 2020. In 2020, $57,241 was paid across 39 transactions to 0 doctors.
The most common payment nature for ALBUTEROL SULFATE is "Unspecified" ($57,241, 100.0% of total).
ALBUTEROL SULFATE is associated with 1 research study, including "CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma" ($57,241).